Professor of Radiation Oncology, University Mich Medical School
Internal Medicine
Dr. Theodore S. Lawrence, MD
|
|
Give Review
Dr. Theodore S. Lawrence practices Internal Medicine. He researched medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine He received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FASCO)" and "Elected Member". Theodore S. Lawrence is a published physician. He has 100 publications published. The most current publication "Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovori..." He is registered with Medicare and accepts Medicare payments.
Publications
- Concurrent whole Brain radiotherapy and RRx-001 for melanoma Brain metastases.
- FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4.
- Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for HepatoCellular Carcinoma.
- Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovori...
- Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.
- A Radiation-Induced Hippocampal Vascular Injury Surrogate Marker Predicts Late Neurocognitive Dysfunction.
- Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
- Quantitative characterizations of ultrashort echo (UTE) images for supporting air-bone separation in the head.
- A statistical evaluation of dose expansion cohorts in phase I clinical trials.
- Targeting mcl-1 for radiosensitization of pancreatic Cancers.
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc.
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer.
- A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic Cancer.
- Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates.
- Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck Cancer: translation from preclinical investigations aiming to improve the ther...
- Low Dose Rate Radiosensitization of HepatoCellular Carcinoma In Vitro and in Patients.
- Estimating functional Liver reserve following hepatic irradiation: Adaptive normal tissue response models.
- Response-driven imaging biomarkers for predicting radiation necrosis of the Brain.
- Milestones in the use of combined-modality radiation therapy and chemotherapy.
- Arterial Perfusion Imaging-Defined Subvolume of Intrahepatic Cancer.
- Improving the Efficacy of Chemoradiation with Targeted Agents.
- KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation.
- Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts.
- ATDC/TRIM29 phosphorylation by ATM/ MAPKAP kinase 2 mediates radioresistance in pancreatic Cancer cells.
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in Cancer.
- Antibody against CD44s Inhibits Pancreatic Tumor Initiation and Post-Radiation Recurrence in Mice.
- Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of Brain tumor response to radiation therapy.
- DCE-MRI defined subvolumes of a brain metastatic lesion by principle component Analysis and fuzzy-c-means clustering for response assessment of radiation therapy.
- Impact of perfusion map Analysis on early survival prediction accuracy in glioma patients.
- HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s.
- Burnout in United States Academic Chairs of Radiation Oncology Programs.
- Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society f...
- Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangioCarcinoma.
- Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition.
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic Cancer.
- Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776.
- Stereotactic body radiation therapy for primary and metastatic Liver tumors.
- Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair.
- Destabilization of the Epidermal Growth Factor Receptor (EGFR) by a Peptide that Inhibits EGFR Binding to Hsp90 and Receptor Dimerization.
- Uncertainty in assessment of radiation-induced diffusion index changes in individual patients.
- Predictive Models for Regional Hepatic Function Based on 99mTc-IDA SPECT and Local Radiation Dose for Physiologic Adaptive Radiation Therapy.
- Physiological imaging-defined, response-driven subvolumes of a tumor.
- DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.
- Tristetraprolin Mediates Radiation-Induced TNF-? ProDuction in Lung Macrophages.
- Regional Variation in Brain White Matter Diffusion Index Changes following Chemoradiotherapy: A Prospective Study Using Tract-Based Spatial Statistics.
- Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy.
- Genetic Variations in TGF?1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Non-Small-Cell Lung Cancer.
- The Quality-of-Life Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
- Protons for Prostate Cancer: the Dream Versus the Reality.
- Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Thera...
- Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung Cancer treated with definitive radiation the...
- Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous Cell carcinoma.
- Sensitization of pancreatic Cancer stem cells to gemcitabine by chk1 inhibition.
- WE-A-217A-01: The Effects of Radiation Therapy on White Matter Fiber Tracts of the Limbic Circuit.
- WE-A-217A-04: Hepatic Function Estimated from HIDA SPECT for Assessment of Liver Response to Radiation Therapy.
- WE-C-BRA-05: Physiological Imaging-Defined Response-Driven Subvolumes of a Tumor.
- WE-G-217A-04: Segmenting Limbic Circuit Fiber Tracts for Quantifying Changes in Diffusion Indices Due to Partial Radiation Therapy.
- DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma.
- Dosimetric Analysis of Radiation-induced Gastric Bleeding.
- A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic...
- Prediction of Liver Function by Using Magnetic Resonance-based Portal Venous Perfusion Imaging.
- A Phase I Clinical and Pharmacology Study Using Amifostine as a Radioprotector in Dose-escalated Whole Liver Radiation Therapy.
- A Research Agenda for Radiation Oncology: Results of the Radiation Oncology Institute's Comprehensive Research Needs Assessment.
- Radiation Therapy with Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer.
- Selective radiosensitization of p53 mutant pancreatic Cancer cells by combined inhibition of Chk1 and PARP1.
- Radiotherapy: The importance of local control in pancreatic Cancer.
- Radiosensitization of human pancreatic Cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
- Concurrent Temozolomide and Dose-Escalated Intensity Modulated Radiation Therapy in Newly Diagnosed Glioblastoma.
- Ablation of breast Cancer stem cells with radiation.
- Modeling the tumor growth profiles in xenograft experiments--response.
- Molecular imaging of akt enables early prediction of response to molecular targeted therapy.
- Diffusion Tensor Imaging of Normal-Appearing White Matter as Biomarker for Radiation-Induced Late Delayed Cognitive Decline.
- Prospective Analysis of parametric MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.
- Baseline Plasma Proteomic Analysis to Identify Biomarkers that Predict Radiation-Induced Lung Toxicity in Patients Receiving Radiation for Non-small Cell Lung Cancer.
- Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
- Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases.
- Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.
- Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate Cancer.
- Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.
- Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung Cancer.
- Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
- Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for Cancer therapy.
- Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck Cancer.
- The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future.
- Recent advances in combined modality therapy.
- Natural proteasome inhibitor celastrol suppresses androgen-independent prostate Cancer progression by modulating apoptotic proteins and NF-kappaB.
- Loss of tumor-initiating Cell activity in cyclophosphamide-treated breast xenografts.
- Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas Cancer.
- Radiotherapy for pancreatic neuroendocrine tumors.
- Radiation increases invasion of gene-modified mesenchymal stem Cells into tumors.
- The impact of the privacy rule on Cancer research: variations in attitudes and application of regulatory standards.
- Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung Cancer: a combined analysis from B...
- Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate Cancer.
- Functional and metabolic magnetic resonance imaging and positron emission tomography for tumor volume definition in high-grade Gliomas.
- Particle therapy in all its parts.
- Role of Cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization.
- The parametric response map is an imaging biomarker for early Cancer treatment outcome.
- Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases.
- Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for prediction of radiation-induced neurocognitive dysfunction.
Schools
Weill Cornell Medical College
Stanford University
Nci
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FASCO)
- Elected Member
Education
-
National Institutes of Health Clinical Center -
Stanford University -
Weill Cornell Medical College of Cornell University
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1144312547 | |
| NPPES Provider LastName | LAWRENCE | |
| NPPES Provider FirstName | THEODORE | |
| NPPES Provider ZIPCode | 481095010 | |
| NPPES Provider State | MI | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 19.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1144312547 |
| Last Name Of The Provider | LAWRENCE |
| First Name Of The Provider | THEODORE |
| View All |
Similar Doctors
|
|
Dr. April D. Campbell, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charitha Gowda, MD |
|
|
Dr. Min Jiang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Qinghui Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca L. MacAllister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Avinash Prabhakar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine A. Persson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashmi Chugh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melissa A. Kovach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heather L. Simpkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monika L. Burness, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne F. Schott, MD
This Doctor is OpenDoctor Recommended.
|